Drug Profile
GSK 461364
Alternative Names: 461364; GSK-461364; GSK461364ALatest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antineoplastics; Small molecules; Thiophenes
- Mechanism of Action Polo-like kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma in United Kingdom (IV, Infusion)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in United Kingdom (IV, Infusion)
- 07 May 2007 Preclinical trials in Cancer in United Kingdom (unspecified route)